The stock's rise snapped a three-day losing streak.

Besides Wall Street's top -and-bottom-line estimates for Edwards Lifesciences (EW), review projections for some of its key metrics to gain a deeper understanding of how the company might have fared ...

After parting ways with its diabetes franchise nearly three years ago, BD is slimming down even further with a plan to divest ...

BDX's overall topline in the first quarter of fiscal 2025 continues to benefit from revenue growth in all segments.

At the request of BD, today's call is being recorded and will be available for replay on BD's Investor Relations website, investors.bd.com or by phone at 1-800-839-2486 for domestic calls and area ...

Our BD 2025 strategy has transformed the company into a faster-growing, more profitable organization positioned at the forefront of long-term growth ...

Wall Street expects flat earnings compared to the year-ago quarter on higher revenues when DexCom (DXCM) reports results for the quarter ended December 2024. While this widely-known consensus outlook ...

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on BeiGene (ONC – Research Report) and Embecta ...

Becton Dickinson said it would focus on medtech and prioritize research, acquisitions and high-growth markets.

In wrapping up the 2023-24 term and embarking on the 2024-25 term, the Supreme Court was asked to decide a number of intellectual property cases. The ...

Watkins brings more than 27 years of experience to Fieldfisher, with a focus on cross-border mergers and acquisitions, PE ...

BD (NYSE: BDX) announced that its board unanimously authorized management to pursue the separation of its Life Sciences business.